Exploring the potential utilities of 99mTc-labeled RBC-equilibrium radionuclide angiocardiography in transfusion-dependent β-thalassemia major patients.
Journal
Nuclear medicine communications
ISSN: 1473-5628
Titre abrégé: Nucl Med Commun
Pays: England
ID NLM: 8201017
Informations de publication
Date de publication:
01 Dec 2021
01 Dec 2021
Historique:
pubmed:
16
8
2021
medline:
5
2
2022
entrez:
15
8
2021
Statut:
ppublish
Résumé
99mTc-labeled RBC-equilibrium radionuclide angiocardiography (ERNA) is done in transfusion-dependent beta-thalassemia major (β-TM) patients routinely for cardiac dysfunction. This prospective study aimed at evaluating the potential of ERNA in demonstrating the bone marrow hyperplasia as an adjunct biomarker for monitoring the adequacy of blood transfusions in transfusion-dependent β-TM patients. One hundred and twenty-six patients of β-TM (study group) and 30 nonthalassemic patients (control) underwent ERNA study with an additional whole-body imaging. We quantitated the normalized bone marrow tracer uptake (due to marrow hyperplasia) and hepatic tracer uptake (indicator of hepatic perfusion) in both the groups on whole-body imaging. Liver and myocardial iron deposition were evaluated with T2* MRI in the thalassemic group. β-TM group showed significantly increased mean normalized marrow count (MN) compared to the control group (P < 0.001) reflecting peripheral marrow hyperplasia (indirect marker for blood transfusion inadequacy). The hematological parameters in the study group showed a negative correlation with MN, without such correlation in the control group. The study group showed greater derangement in hepatic perfusion with significantly less mean normalized hepatic tracer uptake (HN) compared to the control group. Hepatic iron deposition (evaluated with T2* MRI) also showed a negative correlation with hepatic perfusion parameter (HN) assessed by ERNA, though myocardial iron deposition did not show any significant correlation with cardiac systolic/diastolic parameters evaluated by ERNA in the study group. ERNA study with these novel parameters (MN and HN) may have the potential to assess peripheral marrow hyperplasia and derangement in hepatic perfusion in transfusion-dependent β-TM.
Identifiants
pubmed: 34392295
doi: 10.1097/MNM.0000000000001467
pii: 00006231-202112000-00003
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1313-1321Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Origa R. β-thalassemia. Genet Med. 2017; 19:609–619.
Taher AT, Weatherall DJ, Cappellini MD. Thalassaemia. Lancet. 2018; 391:155–167.
Sankaran VG, Nathan DG. Thalassemia: an overview of 50 years of clinical research. Hematol Oncol Clin North Am. 2010; 24:1005–1020.
Rund D, Rachmilewitz E. Beta-thalassemia. N Engl J Med. 2005; 353:1135–1146.
Perisano C, Marzetti E, Spinelli MS, Callà CA, Graci C, Maccauro G. Physiopathology of bone modifications in β-thalassemia. Anemia. 2012; 2012:320737.
Shah FT, Sayani F, Trompeter S, Drasar E, Piga A. Challenges of blood transfusions in β-thalassemia. Blood Rev. 2019; 37:100588.
Taher AT, Saliba AN. Iron overload in thalassemia: different organs at different rates. Hematology Am Soc Hematol Educ Program. 2017; 2017:265–271.
Vichinsky E, Neumayr L, Trimble S, Giardina PJ, Cohen AR, Coates T, et al.; CDC Thalassemia Investigators. Transfusion complications in thalassemia patients: a report from the Centers for Disease Control and Prevention (CME). Transfusion. 2014; 54:972–81; quiz 971.
Poggiali E, Cassinerio E, Zanaboni L, Cappellini MD. An update on iron chelation therapy. Blood Transfus. 2012; 10:411–422.
Tubman VN, Fung EB, Vogiatzi M, Thompson AA, Rogers ZR, Neufeld EJ, Kwiatkowski JL; Thalassemia Clinical Research Network. Guidelines for the standard monitoring of patients with thalassemia: report of the thalassemia longitudinal cohort. J Pediatr Hematol Oncol. 2015; 37:e162–e169.
Shah N, Mishra A, Chauhan D, Vora C, Shah NR. Study on effectiveness of transfusion program in thalassemia major patients receiving multiple blood transfusions at a transfusion centre in Western India. Asian J Transfus Sci. 2010; 4:94–98.
Mitra D, Basu S. Equilibrium radionuclide angiocardiography: Its usefulness in current practice and potential future applications. World J Radiol. 2012; 4:421–430.
Huang H, Nijjar PS, Misialek JR, Blaes A, Derrico NP, Kazmirczak F, et al. Accuracy of left ventricular ejection fraction by contemporary multiple gated acquisition scanning in patients with cancer: comparison with cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2017; 19:34.
Romero-Farina G, Aguade-Bruix S. Equilibrium radionuclide angiography: present and future. J Nucl Cardiol. 2019. doi: 10.1007/s12350-019-01876-9
doi: 10.1007/s12350-019-01876-9
Sachpekidis C, Sachpekidis V, Kopp-Schneider A, Aros G, Moralidis E. Equilibrium radionuclide angiography: intra- and inter-observer repeatability and reproducibility in the assessment of cardiac systolic and diastolic function. J Nucl Cardiol. 2019. doi: 10.1007/s12350-019-01830-9
doi: 10.1007/s12350-019-01830-9
Giubbini R, Milan E. The time for radionuclide ventriculography resurrection is coming. J Nucl Cardiol. 2016; 23:1139–1141.
Villa G, Tommasi L, Colombo B, Balleari E. Medullary hyperplastic hematopoiesis in thalassemia: incidental increased Tc-99m sestamibi bone marrow uptake. Clin Nucl Med. 2005; 30:135–136.
Kumar G, Khadwal A, Sood A, Singh H, Dasagrandhi V, Kashyap S, Mittal BR. What is this image? 2018: Image 3 result: Extramedullary hematopoiesis at unusual site detected with 99mTc-labeled RBC imaging and 18F-FLT PET/CT. J Nucl Cardiol. 2018; 25:1903–1905.
Aflalo-Hazan V, Gutman F, Kerrou K, Montravers F, Grahek D, Talbot JN. Increased FDG uptake by bone marrow in major beta-thalassemia. Clin Nucl Med. 2005; 30:754–755.
Jain T, Khadwal A, Sood A, Kalathoorakath R, Parmar M, Mittal B. Bone marrow hyperplasia detected by gated blood pool imaging. J Nucl Cardiol. 2017; 24:739–741.
Vadi SK, Kashyap S, Sood A, Khadwal A, Parmar M, Parihar AS, Mittal BR. Can 99mTc-labeled RBC-equilibrium radionuclide angiocardiography be an adjunct imaging biomarker for marrow hyperplasia in beta-thalassemia major patients? J Nucl Cardiol. 2019; 26:1380–1382.
Williams TN, Weatherall DJ. World distribution, population genetics, and health burden of the hemoglobinopathies. Cold Spring Harb Perspect Med. 2012; 2:a011692.
De Sanctis V, Kattamis C, Canatan D, Soliman AT, Elsedfy H, Karimi M, et al. β-thalassemia distribution in the old world: an ancient disease seen from a historical standpoint. Mediterr J Hematol Infect Dis. 2017; 9:e2017018.
Mandal S, Sodhi KS, Bansal D, Sinha A, Bhatia A, Trehan A, Khandelwal N. MRI for quantification of liver and cardiac iron in thalassemia major patients: pilot study in Indian population. Indian J Pediatr. 2017; 84:276–282.
El-Beshlawy A, Ragab L, Fattah AA, Ibrahim IY, Hamdy M, Makhlouf A, et al. Improvement of cardiac function in thalassemia major treated with L-carnitine. Acta Haematol. 2004; 111:143–148.
Leon MB, Borer JS, Bacharach SL, Green MV, Benz EJ Jr, Griffith P, Nienhuis AW. Detection of early cardiac dysfunction in patients with severe beta-thalassemia and chronic iron overload. N Engl J Med. 1979; 301:1143–1148.
Davis BA, O’Sullivan C, Jarritt PH, Porter JB. Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. Blood. 2004; 104:263–269.
Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001; 22:2171–2179.
Westwood MA, Wonke B, Maceira AM, Prescott E, Walker JM, Porter JB, Pennell DJ. Left ventricular diastolic function compared with T2* cardiovascular magnetic resonance for early detection of myocardial iron overload in thalassemia major. J Magn Reson Imaging. 2005; 22:229–233.
Fiorillo A, Farina V, D’Amore R, Scippa L, Cortese P, DeChiara C. Longitudinal assessment of cardiac status by echocardiographic evaluation of left ventricular diastolic function in thalassaemic children. Acta Paediatr. 2000; 89:436–441.
Ong ML, Hatle LK, Lai VM, Bosco J. Non-invasive cardiac assessment in beta-thalassaemia major. Int J Clin Pract. 2002; 56:345–348.
Noetzli LJ, Carson SM, Nord AS, Coates TD, Wood JC. Longitudinal analysis of heart and liver iron in thalassemia major. Blood. 2008; 112:2973–2978.
Wahidiyat PA, Liauw F, Sekarsari D, Putriasih SA, Berdoukas V, Pennell DJ. Evaluation of cardiac and hepatic iron overload in thalassemia major patients with T2* magnetic resonance imaging. Hematology. 2017; 22:501–507.
Eghbali A, Taherahmadi H, Shahbazi M, Bagheri B, Ebrahimi L. Association between serum ferritin level, cardiac and hepatic T2-star MRI in patients with major β-thalassemia. Iran J Ped Hematol Oncol. 2014; 4:17–21.